Vinpocetine

General characteristics. Structure:

Active agent: a Vinpocetine - 0,005 g,

Excipients: лудипресс, potato starch, magnesium stearate.

Pharmacological properties:

Pharmacodynamics. Vazodilatiruyushchy means, improves cerebral circulation. Causes brain vasodilatation, strengthening of a blood-groove and improvement of supply of a brain with oxygen and glucose. Vazodilatiruyushchy action of the Vinpocetine is caused by the direct running-down impact on smooth muscles of vessels preferential of a brain. Does not cause a phenomenon of "burglarizing", and strengthens blood supply of ischemic area of a brain, without influencing blood supply of intact areas.
The Vinpocetine increases resistance of cells of a brain to a hypoxia, facilitating transport of oxygen and substrates of power providing to fabrics (owing to reduction of affinity to it of erythrocytes, strengthening of absorption and metabolism of glucose, its switching to energetically more favorable aerobic direction).
The Vinpocetine causes insignificant decrease in system arterial pressure. Promotes accumulation in tsAMF and ATP fabrics (owing to braking of phosphodiesterase and adenylatecyclase stimulation), to increase in maintenance of catecholamines in brain tissues. Improves microcirculation in a brain due to reduction of aggregation of thrombocytes, decrease in viscosity of blood, increase in deformability of erythrocytes.

Pharmacokinetics. At intake it is quickly and completely soaked up in digestive tract. Bioavailability - 60%. Time of achievement of the maximum concentration - 1 h; therapeutic concentration in a blood plasma - 10-20 ng/ml.
Elimination half-life - 4.8-5 h. The Vinpocetine easily gets through gistogematichesky barriers (including through a blood-brain barrier).

Indications to use:

Chronic disturbance of cerebral circulation, state after the postponed acute disorder of cerebral circulation and/or a craniocereberal injury.
Neurologic and mental disturbances at patients with cerebrovascular insufficiency (memory disturbance; dizziness; aphasia, apraxia, motive frustration, headache).
Encephalopathy (hypertensive, posttraumatic).
Vazovegetativny symptomatology in a climacteric.
In ophthalmology: vascular diseases of eyes (degenerative diseases of a choroid, retina or macula lutea; partial occlusions of arteries, secondary glaucoma).
In otorhinolaryngology: decrease in auditory acuity of vascular or toxic genesis, senile relative deafness, Menyer's disease, kokhleovestibulyarny neuritis, sonitus, dizziness of a labyrinth origin.

Route of administration and doses:

Inside, on 5-10 mg 3 times a day. A maintenance dose - 5 mg 3 times a day for a long time.

Features of use:

There are no data.

Side effects:

Lowering of arterial pressure. Seldom - tachycardia, premature ventricular contraction, delay of intra ventricular conductivity.

Interaction with other medicines:

Increases risk of development of hemorrhagic complications against the background of a geparinoterapiya.

Contraindications:

Hypersensitivity, pregnancy, lactation period.
With care - coronary heart disease (a heavy current).

Overdose:

Now about cases of overdose of the drug Vinpocetine it was not reported.

Storage conditions:

In the dry, protected from light place, at a temperature not above 25 °C.
To store in the place, unavailable to children.

Issue conditions:

According to the recipe

Packaging:

Tablets on 5 mg.
On 10 tablets in a blister strip packaging from PVC-aluminum foil.
The 2 or 5 blister strip packagings with the application instruction of drug in a cardboard box.